ZA202001821B - Biomarker - Google Patents

Biomarker

Info

Publication number
ZA202001821B
ZA202001821B ZA2020/01821A ZA202001821A ZA202001821B ZA 202001821 B ZA202001821 B ZA 202001821B ZA 2020/01821 A ZA2020/01821 A ZA 2020/01821A ZA 202001821 A ZA202001821 A ZA 202001821A ZA 202001821 B ZA202001821 B ZA 202001821B
Authority
ZA
South Africa
Prior art keywords
biomarker
Prior art date
Application number
ZA2020/01821A
Other languages
English (en)
Inventor
Alexandre Akoulitchev
Aroul Selvam Ramadass
Ewan Hunter
Matthew Salter
Original Assignee
Oxford Biodynamics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biodynamics Ltd filed Critical Oxford Biodynamics Ltd
Publication of ZA202001821B publication Critical patent/ZA202001821B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2020/01821A 2017-10-02 2020-03-23 Biomarker ZA202001821B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566756P 2017-10-02 2017-10-02
PCT/GB2018/052808 WO2019069067A1 (en) 2017-10-02 2018-10-01 BIOMARKER

Publications (1)

Publication Number Publication Date
ZA202001821B true ZA202001821B (en) 2022-10-26

Family

ID=63834322

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/01821A ZA202001821B (en) 2017-10-02 2020-03-23 Biomarker

Country Status (11)

Country Link
US (1) US12006547B2 (OSRAM)
EP (1) EP3692168A1 (OSRAM)
JP (2) JP2020537514A (OSRAM)
KR (1) KR102762920B1 (OSRAM)
CN (1) CN111344415B (OSRAM)
AU (1) AU2018344573B2 (OSRAM)
CA (1) CA3076450A1 (OSRAM)
MY (1) MY200184A (OSRAM)
SG (1) SG11202002503TA (OSRAM)
WO (1) WO2019069067A1 (OSRAM)
ZA (1) ZA202001821B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2604247B (en) * 2019-09-11 2025-07-02 Oxford BioDynamics PLC Diagnostic chromosome marker
GB202016176D0 (en) * 2020-10-12 2020-11-25 Oxford BioDynamics PLC Disease marker
AU2022206099B2 (en) * 2021-01-07 2023-08-10 Oxford BioDynamics PLC Chromosome interactions
CN117203350A (zh) * 2021-01-07 2023-12-08 牛津生物动力公共有限公司 染色体相互作用
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
BRPI0611702B1 (pt) * 2005-07-04 2015-05-19 Univ Erasmus Medical Ct Captura e caracterização de cromatina co-localizada (4c)
GB0810051D0 (en) * 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
JP5503942B2 (ja) * 2009-10-30 2014-05-28 シスメックス株式会社 疾患の罹患の判定方法
WO2012159025A2 (en) * 2011-05-18 2012-11-22 Life Technologies Corporation Chromosome conformation analysis
US11795496B2 (en) 2015-06-24 2023-10-24 Oxford BioDynamics PLC Epigenetic chromosome interactions
WO2017001568A1 (en) 2015-07-01 2017-01-05 Universitat De Lleida Treatment and prevention of amyotrophic lateral sclerosis
JP7045086B2 (ja) 2016-12-23 2022-03-31 オックスフォード バイオダイナミックス パブリック リミテッド カンパニー 分類法

Also Published As

Publication number Publication date
JP7701419B2 (ja) 2025-07-01
US12006547B2 (en) 2024-06-11
KR102762920B1 (ko) 2025-02-04
NZ762713A (en) 2025-03-28
JP2023182591A (ja) 2023-12-26
KR20200058527A (ko) 2020-05-27
AU2018344573A1 (en) 2020-04-09
JP2020537514A (ja) 2020-12-24
WO2019069067A1 (en) 2019-04-11
CN111344415A (zh) 2020-06-26
CN111344415B (zh) 2024-04-30
US20200407790A1 (en) 2020-12-31
AU2018344573B2 (en) 2020-09-17
SG11202002503TA (en) 2020-04-29
MY200184A (en) 2023-12-12
EP3692168A1 (en) 2020-08-12
CA3076450A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
GB2566681B (en) Biomarker
GB201420908D0 (en) Biomarkers
GB201614455D0 (en) Biomarkers
GB201401603D0 (en) Biomarkers
SG10202007262PA (en) Copanlisib biomarkers
GB201703058D0 (en) Biomarkers
SG10202007322PA (en) Copanlisib biomarkers
SG11202002503TA (en) Biomarker
GB201710858D0 (en) Biomarker
GB201704267D0 (en) Novel biomarker
GB201500729D0 (en) Novel Biomarkers
GB201804648D0 (en) Combination biomarker
GB201703123D0 (en) Biomarkers
GB201512133D0 (en) Biomarkers
GB201420239D0 (en) Biomarker
GB201416015D0 (en) Biomarker
GB201811093D0 (en) Biomarker
GB201704620D0 (en) Combinations
IL268770A (en) Aptamer as a biomarker
GB201603002D0 (en) Inflammation biomarker
GB201707113D0 (en) Biomarker
GB201720776D0 (en) Biomarkers
GB201706669D0 (en) Biomarkers
GB201807367D0 (en) Biomarker
GB201702986D0 (en) Biomarkers